Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOMAL Study of semaglutide in liver transplant candidates with obesity
2026-526953-32-00Phase 3Authorised
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of semaglutide in obesity, type 2 diabetes mellitus (T2DM), hypertension (HTN) and 1 more (2 arms), sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: Percentage change in body weight. Planned start Oct 2026; status: authorised.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)hypertension (HTN)lipid disorder
Beyond the preview
Go deeper on 2026-526953-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526953-32-00.